(917) 310-3371
Low-dose CT screening differs from a chest X-ray and from imaging for symptoms. Under USPSTF, review ages 50–80, at least 20 pack-years and current smoking or quitting within 15 years. Confirm the imaging order, facility and abnormal-result plan. Discuss smoking cessation alongside screening.
Cancer screening looks for disease in people who do not have symptoms. Different tests target different cancers and apply to different risk groups. A screening visit reviews your age, history, prior tests and preferences to choose an appropriate plan. Symptoms or an abnormal screening result need diagnostic assessment rather than another routine screen.
A stool DNA test such as Cologuard, a PSA blood test, low-dose CT lung screening and a multi-cancer blood test do different jobs. A positive result is not by itself a cancer diagnosis. A negative result cannot rule out all cancer. Screening can also produce false positives, unnecessary procedures and overdiagnosis, so benefits and harms should be discussed.
USPSTF recommends colorectal screening for average-risk adults ages 45–75 and individual decisions at 76–85. Its lung recommendation covers ages 50–80 with at least 20 pack-years who currently smoke or quit within 15 years. PSA screening at ages 55–69 is an individual decision under USPSTF; routine screening at 70 or older is not recommended by that guideline. Other organizations may differ, and individual risks matter.
Review previous screening, family history, smoking exposure and symptoms. The clinician explains the recommended test, alternatives, possible results and follow-up. Cologuard is intended for selected average-risk screening; a positive stool screening result requires colonoscopy. High-risk history or concerning symptoms may require a different route from a mail-in stool test.
Bring prior reports and a family cancer history. Ask for the exact collection or imaging instructions. Some stool tests need a supplied kit, while colonoscopy has separate preparation. Tell the team about blood in stool, unexplained weight loss, a persistent new symptom or a previous abnormal result rather than presenting only a request for screening.
Galleri and other multi-cancer detection tests remain distinct from established guideline screening. The current manufacturer and NCI materials reviewed do not establish FDA approval of Galleri; an advisory panel vote is not approval. Such testing does not replace recommended breast, cervical, colorectal or eligible lung screening. Severe bleeding, marked breathing difficulty or other acute symptoms need urgent care.
Before testing, agree on who will review the result and arrange diagnostic follow-up. A positive multi-cancer signal can lead to additional testing without finding cancer. A negative result does not end recommended screening or assessment of symptoms. Track referrals until the receiving practice confirms the next step.
Confirm which tests Nao actually orders or collects, where imaging or colonoscopy occurs and who manages abnormal results. Ask about the test, visit and diagnostic follow-up costs separately.
USPSTF recommends annual low-dose CT screening for adults age 50–80 with at least a 20 pack-year smoking history. They must currently smoke or have quit within the past 15 years. A pack-year is packs per day multiplied by years smoked. Bring smoking dates and prior imaging; quitting longer ago changes eligibility under this recommendation. Discuss smoking cessation, risks and the imaging referral with the clinician. New symptoms require a diagnostic pathway.
No. Recommended lung cancer screening uses low-dose computed tomography, or LDCT, in eligible people. A routine chest X-ray is not an equivalent screening test. Symptoms such as coughing blood or unexplained persistent chest symptoms need diagnostic assessment rather than only a screening booking.
New symptoms need diagnostic assessment rather than only a routine screening test. Tell the clinician about bleeding, a new lump, persistent unexplained pain, bowel changes or unexplained weight loss. A negative screening result does not rule out the cause. Heavy bleeding or severe abdominal pain needs emergency department care now. Call 911 for bleeding that will not stop, fainting, severe breathing difficulty or unsafe travel. Other new or continuing symptoms need diagnostic assessment.
Check the exact insurance product, clinician, location and service with both the office and insurer. A company name, Medicaid or Medicare alone does not establish that every plan is in network. Ask about the visit and test or procedure separately, your copay or deductible, and any referral or authorization requirement. Coverage is not a guarantee of no charge.
Start with the main cancer-screening page for colorectal, Galleri, cervical, PSA, and lung-screening planning across the Nao network.
Use the Cologuard page for direct at-home colorectal-screening booking and follow-up planning.
Compare stool-based screening and colonoscopy options with clear next-step guidance.
Review multi-cancer early-detection planning, who may consider Galleri, and what it does not replace.
Use the cervical-screening page for Pap smear questions, HPV co-testing context, and local women's-health clinic access.
Handle prostate-screening timing, shared-decision questions, and PSA blood-test planning through primary care.